This article was originally published in The Gray Sheet
Executive SummaryPresident and CEO David Sutcliffe resigns. Sutcliffe, who has held the positions since March 1992, will stay at the firm until a replacement is appointed
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.